About OJO | Search | Ahead of print | Current Issue | Archives | Author Instructions | Reviewer Guidelines | Online submissionLogin 
Oman Journal of Ophthalmology Oman Journal of Ophthalmology
  Editorial Board | Subscribe | Advertise | Contact
https://www.omanophthalmicsociety.org/ Users Online: 354  Wide layoutNarrow layoutFull screen layout Home Print this page  Email this page Small font size Default font size Increase font size
ORIGINAL ARTICLE
Year : 2011  |  Volume : 4  |  Issue : 1  |  Page : 10-16

Combined intravitreal bevacizumab with phacoemulsification in visually significant cataract and visually significant exudative maculopathy


1 Department of Ophthalmology, AUB, 3 Daghammarskjold Plaza, 8th floor, New York, NY 10017-2303, USA
2 Department of Ophthalmology, American University of Beirut, Beirut, Lebanon
3 Department of Human Biology, Baylor College of Medicine, One Baylor Plaza, Anderson Hall-Suite 630E, Houston, Texas 77030,U.S.A
4 Department of Population Statistics, American University of Beirut, Beirut, Lebanon

Correspondence Address:
Ahmad Mansour
Department of Ophthalmology, American University of Beirut, P.O.B 113-6044, Beirut, Lebanon

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-620X.77656

Rights and Permissions

Purpose : We investigated the visual outcome of combined phacoemulsification with intravitreal bevacizumab, in eyes with dense cataract and visually significant exudative maculopathy. Materials and Methods : Prospective longitudinal pilot study of consecutive patients treated by two surgeons in 2006, using intravitreal bevacizumab at the end of phacoemulsification. The historical control group consisted of consecutive subjects with exudative maculopathy and dense cataract treated by the same surgeons with the help of phacoemulsification without intravitreal bevacizumab prior to 2006. Results : Thirty-one treated patients had the mean (SD) logMar best corrected visual acuity improving from - 1.48 (0.50) preoperatively to - 0.67 (0.38) in the first postoperative week ( p < 0.001), to - 0.64 (0.40) in the first postoperative month ( p < 0.001), and to - 0.62 (0.42) ( p < 0.001) on the last follow-up (mean 4.2 months, range 1 - 9 months). Fourteen control patients had the mean (SD) logMar best corrected visual acuity improving from - 1.78 (0.79) preoperatively, to - 0.91 (0.53) in the first postoperative week ( p < 0.001), to - 0.86 (0.45) in the first postoperative month ( p < 0.001), and to - 0.90 (0.47) ( p < 0.001) on the last follow- up (mean 19.6 months, range 1 - 49 months). Initial visual acuities, final visual acuities, and percentage of visual improvement at one month were all not significantly better in the intervention compared to the control group at one month. In the study group, the fovea was flattened at the one-month follow-up, by 90-diopter slit lamp examination and / or Optical coherence tomography. Conclusion : The combination of intravitreal bevacizumab and phacoemulsification is beneficial for maximal visual rehabilitation in the first postoperative month.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3715    
    Printed214    
    Emailed1    
    PDF Downloaded572    
    Comments [Add]    

Recommend this journal